Open AccessPramipexole to Improve Cognition in Bipolar Disorder
Author(s) -
Anna Van Meter,
M. Mercedes PerezRodriguez,
Raphael J. Braga,
Megan Shanahan,
Lauren Hanna,
Anil K. Malhotra,
Katherine E. Burdick
Publication year - 2021
Publication title -
journal of clinical psychopharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001407
Subject(s) - pramipexole , neurocognitive , mood , placebo , bipolar disorder , psychology , dopamine agonist , randomized controlled trial , cognition , medicine , psychiatry , dopamine , parkinson's disease , dopaminergic , alternative medicine , disease , pathology
Adults with bipolar disorder (BD) often experience neurocognitive impairment that negatively impacts functioning and quality of life. Previous trials have found that dopamine agonist agents improve cognition in healthy volunteers and that adults with BD who have stable mood and mild cognitive deficits may also benefit. We hypothesized that pramipexole, a dopamine agonist, would improve neurocognitive function in patients with BD.